MX394337B - Metodo y composiciones para el tratamiento de infeccion por coronavirus - Google Patents

Metodo y composiciones para el tratamiento de infeccion por coronavirus

Info

Publication number
MX394337B
MX394337B MX2020009095A MX2020009095A MX394337B MX 394337 B MX394337 B MX 394337B MX 2020009095 A MX2020009095 A MX 2020009095A MX 2020009095 A MX2020009095 A MX 2020009095A MX 394337 B MX394337 B MX 394337B
Authority
MX
Mexico
Prior art keywords
compositions
coronavirus infection
treating coronavirus
viral infection
treating
Prior art date
Application number
MX2020009095A
Other languages
English (en)
Other versions
MX2020009095A (es
Inventor
Otis C Addington
Richard Obiso
Robert A Newman
Original Assignee
Phoenix Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/895,920 external-priority patent/US10729735B1/en
Application filed by Phoenix Biotechnology Inc filed Critical Phoenix Biotechnology Inc
Publication of MX2020009095A publication Critical patent/MX2020009095A/es
Publication of MX394337B publication Critical patent/MX394337B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un método de tratamiento de una infección viral, tal como una infección viral provocada por un virus de la familia Coronaviridae; se utiliza una composición que tiene por lo menos oleandrina para tratar la infección viral.
MX2020009095A 2020-03-31 2020-07-14 Metodo y composiciones para el tratamiento de infeccion por coronavirus MX394337B (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063002735P 2020-03-31 2020-03-31
US202063010246P 2020-04-15 2020-04-15
US202063014294P 2020-04-23 2020-04-23
US202063017263P 2020-04-29 2020-04-29
US202063021512P 2020-05-07 2020-05-07
US202063029530P 2020-05-24 2020-05-24
US202063034800P 2020-06-04 2020-06-04
US16/895,920 US10729735B1 (en) 2016-09-14 2020-06-08 Method and compostitions for treating coronavirus infection
US202063042656P 2020-06-23 2020-06-23
US202063051576P 2020-07-14 2020-07-14
PCT/US2020/042009 WO2021201903A1 (en) 2020-03-31 2020-07-14 Method and compositions for treating coronavirus infection

Publications (2)

Publication Number Publication Date
MX2020009095A MX2020009095A (es) 2022-07-28
MX394337B true MX394337B (es) 2025-03-24

Family

ID=77930101

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020009095A MX394337B (es) 2020-03-31 2020-07-14 Metodo y composiciones para el tratamiento de infeccion por coronavirus
MX2022009176A MX2022009176A (es) 2020-03-31 2020-08-31 Metodo y composiciones para el tratamiento de infeccion por coronavirus.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022009176A MX2022009176A (es) 2020-03-31 2020-08-31 Metodo y composiciones para el tratamiento de infeccion por coronavirus.

Country Status (8)

Country Link
JP (2) JP7153083B2 (es)
KR (2) KR102464428B1 (es)
IL (2) IL277315B (es)
MX (2) MX394337B (es)
RU (1) RU2020130238A (es)
SG (1) SG11202105728YA (es)
TW (2) TWI790048B (es)
WO (1) WO2021201903A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021282086A1 (en) * 2020-05-24 2023-01-05 Phoenix Biotechnology, Inc. Extract containing oleandrin and method of production thereof
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
AU2022329917A1 (en) * 2021-08-16 2024-03-07 Phoenix Biotechnology, Inc. Method and compositions for treating animal viral infections
US20250288632A1 (en) * 2022-04-29 2025-09-18 Emory University Viral Entry Inhibitors Derived From Botanicals
CN115364136A (zh) * 2022-09-05 2022-11-22 深圳市药品检验研究院（深圳市医疗器械检测中心） 景天科植物提取物在制备抗新型冠状病毒和流感病毒感染药物中的应用
CN116350637A (zh) * 2023-03-09 2023-06-30 中国人民解放军空军军医大学 胆固醇及其代谢相关物质在制备抑制汉坦病毒感染药物中的用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1394196A (en) 1971-10-03 1975-05-14 Hisamitsu Pharmaceutical Co Process for isolating oleandrin from nerium odorum
FI872106A7 (fi) 1986-05-13 1987-11-14 Huseyin Ziya Ozel Nerium-lajien uutteita, menetelmä niiden valmistamiseksi ja niiden käyttö.
JPS6333341A (ja) * 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd 配糖体の処理方法
US5236132A (en) 1992-01-03 1993-08-17 Vortec, Inc. Gradient-force comminuter/dehydrator apparatus and method
US5598979A (en) 1995-04-20 1997-02-04 Vortec, Inc. Closed loop gradient force comminuting and dehydrating system
CA2191923C (en) 1996-12-03 2000-10-24 Ji-Won Yoon Portulaca oleracea and tumor cell growth
IL139307A0 (en) 1998-05-19 2001-11-25 Res Dev Foundation Triterpene compositions and methods for use thereof
CA2354037A1 (en) 1998-09-24 2000-03-30 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
US6517015B2 (en) 2000-03-21 2003-02-11 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
EP1309605A1 (en) 2000-08-18 2003-05-14 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv
US6715705B2 (en) 2001-03-16 2004-04-06 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
ATE295087T1 (de) 2001-04-09 2005-05-15 Loders Croklaan Bv Konzentrat von triterpenen
WO2002091858A1 (en) 2001-05-11 2002-11-21 University Of Ottawa Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
WO2002102395A1 (en) 2001-06-18 2002-12-27 S.A.V Virex Co Ltd Nerium oleander extract, compositions containing the nerium oleander l. extract and a method of preparation of this extract
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US7179484B2 (en) 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
WO2004087121A2 (en) 2003-03-28 2004-10-14 Azaya Therapeutics, Inc. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
EP1788967B1 (en) 2004-08-13 2013-06-12 Biolase, Inc. Laser handpiece architecture and methods
EP1858910B1 (en) 2005-02-09 2010-11-03 Dabur Pharma Ltd. Novel betulinic acid derivatives a-ring-condensed to a heterocyclic group
US20090076290A1 (en) 2005-03-29 2009-03-19 Regents Of The University Of Minnesota Selective oxidation of triterpenes employing tempo
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
US20090131714A1 (en) 2005-06-08 2009-05-21 Krasutsky Pavel A Synthesis of betulonic and betulinic aldehydes
CA2611435C (en) 2005-06-10 2013-01-08 Pola Chemical Industries Inc. Novel triterpenic acid derivative and preparation for external application for skin comprising the same
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
AU2006333084A1 (en) 2005-12-16 2007-07-12 Panacos Pharmaceuticals, Inc. Preparation of pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
EP1803461A1 (en) 2005-12-27 2007-07-04 Heinz-Herbert Fiebig Therapeutic use of an extract from the leaves of Nerium oleander
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
US20090203661A1 (en) 2006-10-12 2009-08-13 Safe Stephen H Betulinic acid, derivatives and analogs thereof and uses therefor
TW200837074A (en) 2006-11-03 2008-09-16 Panacos Pharmaceuticals Inc Extended triterpene derivatives
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
RU2571687C2 (ru) 2007-11-13 2015-12-20 Феникс Байотекнолоджи Инк. Набор для определения вероятности терапевтического ответа на противораковую химиотерапию сердечным гликозидом
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
CN104250280A (zh) 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
US20110224159A1 (en) 2008-09-10 2011-09-15 Universite du Quebec a Chicoutime Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
RU2530654C2 (ru) 2008-10-14 2014-10-10 Нериум Биотекнолоджи, Инк. Способ экстракции сердечных гликозидов и композиции на их оcнове
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
CN101704872B (zh) 2009-11-23 2012-06-27 张南 23-羟基白桦酸衍生物、其制备方法及应用
US8685469B2 (en) 2009-11-30 2014-04-01 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US8481086B2 (en) 2010-01-11 2013-07-09 Phoenix Biotechnology, Inc. Method of treating neurological conditions with cardiac glycoside
TWI386415B (zh) 2010-02-02 2013-02-21 Univ Kaohsiung Medical 熊果酸衍生物及其醫藥組合物
TWI410431B (zh) 2010-12-22 2013-10-01 Ind Tech Res Inst 齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途
WO2012095705A1 (en) 2011-01-10 2012-07-19 Hetero Research Foundation Pharmaceutically acceptable salts of novel betulinic acid derivatives
HRP20151212T1 (hr) 2011-01-31 2015-12-04 Bristol-Myers Squibb Company C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
CN102558280B (zh) 2011-11-18 2014-09-17 温州大学 一种30-卤代桦木酸的生产方法
NO2786757T3 (es) 2011-12-01 2018-01-13
DK2787002T3 (en) 2011-12-01 2016-08-29 Hangzhou Bensheng Pharmaceutical Co Ltd Oleanolsyreamidat derivatives, methods of making and uses thereof
WO2013160810A2 (en) 2012-04-24 2013-10-31 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
WO2014027777A2 (ko) 2012-08-14 2014-02-20 한국콜마 주식회사 신규한 우르솔릭산 유도체 및 이의 제조 방법
HRP20171565T1 (hr) 2012-09-10 2017-12-15 Reata Pharmaceuticals, Inc. C17-heteroaril derivati oleanolne kiseline i postupci njihove uporabe
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
JP6186012B2 (ja) 2013-02-25 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ−３アルキルおよびアルケニル修飾ベツリン酸誘導体
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
WO2017214080A1 (en) * 2016-06-09 2017-12-14 University Of Massachusetts Inhibition of zika virus infection
ES2874187T3 (es) 2016-09-14 2021-11-04 Phoenix Biotechnology Inc Método y composiciones para el tratamiento de una infección viral
US10702567B2 (en) * 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
CA3075729A1 (en) * 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Use of oleandrin to treatn viral infection

Also Published As

Publication number Publication date
WO2021201903A1 (en) 2021-10-07
JP7153083B2 (ja) 2022-10-13
TW202137991A (zh) 2021-10-16
KR102464428B1 (ko) 2022-11-04
IL277315B (en) 2022-05-01
TW202211926A (zh) 2022-04-01
MX2020009095A (es) 2022-07-28
IL291727B1 (en) 2023-03-01
IL291727A (en) 2022-05-01
MX2022009176A (es) 2022-08-17
TWI790048B (zh) 2023-01-11
TWI753747B (zh) 2022-01-21
KR20210124010A (ko) 2021-10-14
RU2020130238A (ru) 2022-03-14
JP2022186737A (ja) 2022-12-15
IL291727B2 (en) 2023-07-01
RU2020130238A3 (es) 2022-03-14
IL277315A (en) 2021-09-30
SG11202105728YA (en) 2021-11-29
JP2022522074A (ja) 2022-04-14
KR20220151038A (ko) 2022-11-11

Similar Documents

Publication Publication Date Title
MX2020009095A (es) Metodo y composiciones para el tratamiento de infeccion por coronavirus.
EA202193251A1 (ru) Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
MX2023014307A (es) Inhibidores de proteasa como antivirales.
ZA202207169B (en) Methods, compositions, and vaccines for treating a virus infection
ZA202500439B (en) Therapeutic compounds for hiv virus infection
WO2021188969A3 (en) Coronavirus vaccines and methods of use
BR112023020798A2 (pt) Método para tratar ou prevenir uma infecção, e, uso de um composto
MX2022013749A (es) Metodos y composiciones para el tratamiento del coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2).
ZA202306360B (en) Substituted pyridotriazine compounds and uses thereof
UA118080C2 (uk) Противірусні сполуки
MX2019002978A (es) Composiciones que comprenden una bacteria no patogena y metodos para proteger plantas y animales anfitriones contra enfermedades micoticas, bacterianas y virales.
MX2020002883A (es) Método y composiciones para tratar la infección viral.
ZA202302276B (en) Methods and compositions for treating coronavirus infections
ZA202209180B (en) Compositions and methods for treating long covid
WO2023054732A3 (ja) 新型コロナウイルス感染症治療用医薬
UY39313A (es) Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
MX2024006374A (es) Composiciones y metodos de bioproteccion basados en microalgas para plantas hospederas.
EA202192454A1 (ru) Новый ингибитор mek для лечения вирусных и бактериальных инфекций
WO2021202103A3 (en) Method and compositions for treating coronavirus infection
PH12021551062A1 (en) Method and compositions for treating coronavirus infection
MX2021014579A (es) Metodo y composiciones para tratar una infeccion por el virus linfotropico humano de celulas t tipo 1.
BR112023016958A2 (pt) Compostos para uso no tratamento de uma infecção por vírus envelopado
WO2022032112A3 (en) Compositions and methods for treating a coronavirus infection
MX2024002621A (es) Partículas similares a virus para el tratamiento o prevención de una infección por un virus coronaviridae.
MX2024003776A (es) Inhibidores de infección por molluscum contagiosum y métodos de uso de los mismos.